Insights & Resources

Explore ASC 805’s role in bringing clarity to business combinations — from fair value measurements to goodwill and beyond.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

Companies looking to transform their operations through AI will need to guard against risk from vendors without a SOC 2 report. Learn more here.

Due diligence is a crucial step in any merger and acquisition process. This can be especially challenging for Software-as-a-Service (SaaS) companies.

With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.

Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

Weaver’s current guidance on navigating the AI landscape includes tips to help avoid deceptive tactics and questions to ask when vetting a vendor.

Dashboards are catalysts for decision-making and operational excellence when businesses incorporate user-centric design and include key insights and alerts.

Leverage digital transformation and IT optimization to drive business success by harnessing contextualized data, streamlining processes and fostering innovation.

Unlock AI's potential with quality data. Learn key steps to build a strong data governance framework, integrate data and foster a data-driven culture for AI success.